Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid tumors, and Valo Therapeutics (Valo Tx) have entered a collaboration to evaluate PeptiCRAd technology as a tool to coat ONCOS oncolytic adenoviruses with Targovax’s TG mutant RAS peptides.   Valo Tx’s PeptiCRAd technology has been developed to coat oncolytic viruses with tumor antigen peptides for enhanced immune activation and local delivery of ant...